Evidence map›Paper›PMID 20181281›Full record

ArticleBMC cancer2010

Angiotensin II type 2 receptor signaling significantly attenuates growth of murine pancreatic carcinoma grafts in syngeneic mice.

Chiyo Doi, Noboru Egashira, Atsushi Kawabata, Dharmendra Kumar Maurya, Naomi Ohta, Deepthi Uppalapati, Rie Ayuzawa, Lara Pickel, Yuka Isayama, Deryl Troyer and 2 more

Open access · goldAbstract read
In one paragraph

Article in BMC cancer, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed, 1 pooled it
3.5field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 1 synthesis or guideline pooled it, 68 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. RSC medicinal chemistry · 2023
    Article
  4. The Angiotensin ATPharmacological reviews · 2022
    Review
  5. Article
  6. Article
  7. Article
  8. Renin-angiotensin system and cancer: epidemiology, cell signaling, genetics and epigenetics.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2021
    Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 2 countries.

Chiyo DoiDepartment of Anatomy & Physiology, Kansas State University, College of Veterinary Medicine, Manhattan, KS 66506, USA.
Noboru Egashira
Atsushi Kawabata
Dharmendra Kumar Maurya
Naomi Ohta
Deepthi Uppalapati
Rie Ayuzawa
Lara Pickel
Yuka Isayama
Deryl Troyer
Susumu Takekoshi
Masaaki Tamura
Kansas State University · USTokai University · JP

Funding

TRANSEPITHELIAL ION TRANSPORT &ITS REGULATIONP20RR017686 · NCRR · KANSAS STATE UNIVERSITY · PI MELGAREJO GARCIA, LUIS TONATIUH · 2002 to 2011
$21.8M
WEIGHT CONTROL, CELL SIGNALING AND CANCER PREVENTIONP20RR015563 · NCRR · UNIVERSITY OF KANSAS LAWRENCE · PI ZUFFEREY, RACHEL · 2000 to 2009
$20.1M
Stem cells as vehicles for therapeutic nanoparticle delivery to breast cancerR21CA135599 · NCI · KANSAS STATE UNIVERSITY · PI TROYER, DERYL LEE · 2008 to 2009
$359k
NCI NIH HHS 1R21CA135599NCRR NIH HHS 5P20RR015563NCRR NIH HHS P20 RR017686
6 · The paper itself

Abstract

backgroundPancreatic cancer is one of the most aggressive human malignancies, with a very poor prognosis. To evaluate the effect of angiotensin II (Ang II) type 2 receptor (AT2) expression in the host's body on the growth of pancreatic carcinoma, we have investigated the growth of mouse pancreatic ductal carcinoma grafts in syngeneic wild type and AT2 receptor-deficient (AT2-KO) mice.

methodsThe role of AT2 receptor-signaling in stromal cells on the growth of murine pancreatic carcinoma cells (PAN02) was studied using various in vitro and in vivo assays. In vivo cell proliferation, apoptosis, and vasculature in tumors were monitored by Ki-67 immunostaining, TUNEL assay, and von Willebrand factor immunostaining, respectively. In the co-culture study, cell proliferation was measured by MTT cell viability assay. All the data were analyzed using t-test and data were treated as significant when p < 0.05.

resultsOur results show that the growth of subcutaneously transplanted syngeneic xenografts of PAN02 cells, mouse pancreatic ductal carcinoma cells derived from the C57/BL6 strain, was significantly faster in AT2-KO mice compared to control wild type mice. Immunohistochemical analysis of tumor tissue revealed significantly more Ki-67 positive cells in xenografts grown in AT2-KO mice than in wild type mice. The index of apoptosis is slightly higher in wild type mice than in AT2-KO mice as evaluated by TUNEL assay. Tumor vasculature number was significantly higher in AT2-KO mice than in wild type mice. In vitro co-culture studies revealed that the growth of PAN02 cells was significantly decreased when grown with AT2 receptor gene transfected wild type and AT2-KO mouse-derived fibroblasts. Faster tumor growth in AT2-KO mice may be associated with higher VEGF production in stromal cells.

conclusionsThese results suggest that Ang II regulates the growth of pancreatic carcinoma cells through modulating functions of host stromal cells; Moreover, Ang II AT2 receptor signaling is a negative regulator in the growth of pancreatic carcinoma cells. These findings indicate that the AT2 receptor in stromal fibroblasts is a potentially important target for chemotherapy for pancreatic cancer.

Indexed as

Gene Expression Regulation, NeoplasticAnimalsCarcinomaCell Line, TumorCell ProliferationCell SurvivalCoculture TechniquesMiceMice, Inbred C57BLMice, KnockoutPancreatic NeoplasmsReceptor, Angiotensin, Type 2Signal TransductionTetrazolium SaltsThiazolesvon Willebrand FactorReceptor, Angiotensin, Type 2Tetrazolium SaltsThiazolesthiazolyl bluevon Willebrand Factor

Identifiers

PMID20181281
PMCPMC2846883
OpenAlexW2005007397

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.